中国大型肾细胞癌队列中ALK重排肾细胞癌的遗传学与临床病理特征及文献回顾
本研究从477例中国肾细胞癌患者组织中筛选ALK重排病例,通过免疫组化、FISH和荧光定量RT-PCR鉴定出2例ALK重排肾细胞癌,分别检测到TPM3-ALK和EML4-ALK融合转录本。结合文献报道的8例,共10例ALK重排肾细胞癌的5年癌特异性生存率低于ISUP G1-G3透明细胞肾细胞癌和乳头状肾细胞癌,但高于G4透明细胞肾细胞癌和乳头状肾细胞癌。ALK重排肾细胞癌是罕见亚型,具有独特组织学特征和不良预后,识别该亚型对ALK抑制剂治疗有重要临床意义。
要点
- 检测到TPM3-ALK和EML4-ALK两种融合转录本。
- 10例ALK重排肾细胞癌的5年癌特异性生存率低于G1-G3透明细胞和乳头状肾细胞癌,高于G4。
核心结论
- ALK重排肾细胞癌是成人肾细胞癌的罕见亚型,具有独特组织学特征和不良预后。
- 识别ALK重排肾细胞癌具有重要临床意义,患者可能受益于ALK抑制剂治疗。
研究设计与样本
- 研究纳入477例中国肾细胞癌患者组织构建组织芯片进行免疫组化筛查。
- 采用FISH和荧光定量RT-PCR鉴定并确认ALK重排及融合基因。
- 随访分析2例本组病例及文献报道的8例ALK重排肾细胞癌。
主要发现
- FISH显示两例肿瘤分别呈1R1G1F和2R2G信号模式,提示ALK重排。
- 荧光定量RT-PCR分别检测到TPM3-ALK和EML4-ALK融合转录本。
- 2例患者分别于术后第16个月和第48个月死于肾细胞癌。
- 10例ALK重排肾细胞癌的5年癌特异性生存率低于ISUP G1、G2、G3透明细胞肾细胞癌和乳头状肾细胞癌,但高于G4透明细胞肾细胞癌和乳头状肾细胞癌。
关键数值与推荐
- ALK重排肾细胞癌的5年癌特异性生存率低于ISUP G1-G3透明细胞肾细胞癌和乳头状肾细胞癌。
- ALK重排肾细胞癌的5年癌特异性生存率高于ISUP G4透明细胞肾细胞癌和乳头状肾细胞癌。
临床怎么用
- 对肾细胞癌病例应关注ALK重排亚型,必要时行FISH或RT-PCR确认。
- 确诊ALK重排肾细胞癌的患者可能从ALK抑制剂治疗中获益。
- ALK重排肾细胞癌预后较差,需加强随访监测。
局限性
- 本研究仅检出2例ALK重排肾细胞癌,样本量小。
- 文献回顾仅纳入8例已报道病例,总例数有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (RCC) is a rare subtype of RCC reported in recent years, with eight cases so far. The aims of the present study were to screen ALK-rearranged cases from a large cohort of RCCs in China to determine the frequency of ALK rearrangement and investigate the clinicopathological features and outcomes. METHODS AND RESULTS: Tissues from a total of 477 RCC patients in China were embedded into tissue microarrays for immunostaining. Fluorescence in-situ hybridization (FISH) and fluorescence quantitative reverse transcription polymerase chain reaction (RT-PCR) were applied to identify and confirm the rearrangement of ALK, and to identify the genes fused with ALK. ALK expression was identified in two of 477 RCCs. By FISH analysis, the two tumours showed either a 1R1G1F or a 2R2G signal pattern, indicating rearrangement involving ALK. Fluorescence quantitative RT-PCR detected the TPM3-ALK fusion and EML4-ALK fusion transcripts in the two tumours, respectively. Follow-up data were analyzed for the two cases and eight other ALK-rearranged RCCs reported in the literature. Two patients died from RCCs, on the 16th month and 48th month after surgery, respectively. The 5-year cancer-specific survival rate of patients with the 10 ALK-rearranged RCCs was lower than that of patients with International Society of Urological Pathology (ISUP) G1, G2 and G3 clear cell RCC (CCRCC) and papillary RCC (PRCC), but higher than that of patients with G4 CCRCC and PRCC. CONCLUSIONS: ALK-rearranged RCC is a rare subtype of adult RCC and is associated with distinct histological features and a poor prognosis. Identification of ALK-rearranged RCC has important clinical significance, because patients might benefit from ALK inhibitor therapy as used in lung adenocarcinoma.
引用
- Yu W, Wang Y, Jiang Y, et al. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review. Histopathology. 2017. PMID: 28199742. doi:10.1111/his.13185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。